Generics 19

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Sugammadex manufacturers

19 products found

Filters

19 products found

sugammadex

Vials, injection 100 mg/ml - 5 ml, 2 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Available for
Distribution only
Comments
Ref: Bridion®
Manufacturer #10720

It is one of the oldest pharmaceutical companies specializing in generic mostly for the hospital segment. The key products offered are life-saving medicines, especially in the CNS and cardiovascular therapeutic group. The company follows and complies with the EU GMP requirements.

Manufacturer usually replies in 4 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Estonia , Latvia , Lithuania
Manufacturer #2346

Manufacturer usually replies in 7 days

sugammadex

Solution for injection 200 mg/2 ml, 500 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Kosovo
Manufacturer #298

Manufacturer usually replies in 3 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Armenia , Azerbaijan , Greece , Iraq , Israel , Kazakhstan , Kosovo , Libya , Tajikistan , Uzbekistan , Vietnam
Available for
Licensing with supply, Distribution only
Manufacturer #17046

It is one of the fastest-growing pharmaceutical firms and a top investor in Rx and Healthcare solutions. The company has been awarded several prizes for its performance and growing business units and has recently been characterized as one of the local economy gems. Based in Europe.

Manufacturer usually replies in 6 days

sugammadex

Solution for injection 200 mg / 2 ml, 500 mg/ 5 ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Ireland , Italy , Serbia , United Kingdom , Vietnam
Available for
Licensing with supply
Manufacturer #12180
It is a pharmaceutical company focused on discovering, licensing, and manufacturing generics and added-value medications that meet stringent quality standards set by the FDA and the EMA. They design and produce in accordance with European quality standards. They have over 30 years of experience and have completed over 30 licensing agreements around the world.

Manufacturer usually replies in 6 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Storage below +30 C
Manufacturer #1586
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe, the Middle East, CIS, LATAM, and Asia for 10+ years. The company's production lines are GMP-compliant. Main dosage forms include solid, liquid, and injection. The company prepares dossier in EU CTD format.

Manufacturer usually replies in 6 days

sugammadex

Injection 200 mg/2 ml, 500 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP, ANVISA
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
RLD-Bridion (MSD) (RX) Dossier availability date: Q3 2025
Manufacturer #19992
A pharmaceutical manufacturer based in the EU that is active in 20+ countries selling its products for 190+ years. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are GMP-compliant. Main therapy areas include anti-infectives, dermatology, and CNS. The company products are prepared in CTD dossier format.

Manufacturer usually replies in 6 days

sugammadex

Vials 100 mg/ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
MAs for sale
France , Germany , Italy , Spain
Comments
DCP approved
Manufacturer #276

Manufacturer usually replies in nan days

sugammadex

Vials 100 mg/ml - 2 ml, 5 ml

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
FDA, EU GMP
Manufacturer #276

Manufacturer usually replies in nan days

sugammadex

Solution for injection 100 mg/ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Unavailable markets
Bulgaria , Costa Rica
Manufacturer #361
It is a global player with more than half a century of experience. It has more than 4 facilities to operate from. They have marketing and promotion in more than 20 countries. It exports to more than 50 countries. The only motto is to improve the quality of human life and to provide access to reliable, high-quality products for human health worldwide. It is focused to create its own cadres in every country it operates.

Manufacturer usually replies in 9 days

sugammadex

Solution for injection 100 mg/1 ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Unavailable markets
Albania
Available for
Licensing with supply
Manufacturer #281
It is a leading European pharmaceutical firm that strives to create a powerful global brand with innovative goods and services, as well as bold and pioneering activities, by working passionately to heal the lives they touch. The business was founded in the 1900s. In the interest of public health and the national economy, the firm launched the project to promote public awareness about the unintentional use of medications.

Manufacturer usually replies in 8 days

sugammadex

Injection 100 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Manufacturer #10627

Manufacturer usually replies in 9 days

sugammadex

Vials, injection 200 mg/2 ml, 500 mg/5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

sugammadex

Solution for injection 200 mg/2 ml , 500 mg/5 ml - 2 ml, 5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, PICS
Manufacturer #2272
The company integrates and applies enormous experience and technology in the field of hospital products. Their goal is to become a global leader in intensive care units and maintain that position. The company's headquarters were established in Europe in 1980ies, and serum production was continuing in a plant in Europe till the end of the 2000s. With a nationwide market share of 50%, it has become one of the leading serum producers. They've already started making the first ready-to-use injections.

Manufacturer usually replies in 7 days

sugammadex

Vials, injection 100 mg / ml

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9406

Manufacturer usually replies in 7 days

sugammadex

Injection 100 mg/ml, 200 mg/ml - 2 ml, 5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 7 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, PICS
Manufacturer #2760

Manufacturer usually replies in 5 days

sugammadex

Solution for injection 100 mg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Brazil
GMP approvals
ANVISA
Manufacturer #463

Manufacturer usually replies in 11 days

Sugammadex

Sugammadex is a medication prescribed in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. It is the first selective relaxant binding agent (SRBA) in general anesthesia. Usage of the aminosteroid non-depolarizing neuromuscular-blocking agents such as vecuronium or rocuronium results in the neuromuscular blockade. Sugammadex is a unique and novel cyclodextrin. Termed a neuromuscular reversal drug, it is the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade. Sugammadex is effective in reversing moderate or deep cases of neuromuscular blockade. Doctors around the world are looking forward to sugammadex eliminating many of the shortcomings of the general anesthetic practice, specifically in the context of antagonism to rocuronium and other aminosteroid muscle relaxants.
Sugammadex is sold under the brand name Bridion. Merck pharm now owns and sells Sugammdex. However, Organon pharmaceutical company at the Newhouse Research Site in Scotland discovered Sugammdex but Organon was bought by Schering-Plough in 2007. Schering-Plough later merged with Merck in 2009. While Sugammadex got approval for use in the European Union in 2008, the US Food and Drug Administration initially rejected Schering-Plough’s New Drug Application for Sugammadex in 2008. However, it was eventually approved for sales in the United States in 2015.

Forms and Dose

Sugammadex is both available and administered as a single bolus injection. For reversing the neurotransmission blockage by rocuronium and vecuronium, the standard adult dose is 4 mg per kilo of body weight. If spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts and there are no twitch responses to train-of-four stimulation, the recommended adult dose is 2 mg per kilo of body weight is recommended if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. For reversing Rocuronium effects only, the recommended adult dose is 16 mg per kilo if there is a clinical need to reverse neuromuscular blockade soon within 3 minutes of administration of a single dose of 1.2 mg per kilo.

The price of Sugammadex

In the USA, consumers have to pay around $1,103 for a supply of 20 milliliters for an intravenous solution (100 mg/mL). and in Australia, the cost of a 200mg vial of Sugammadex varies from A$45 to 195, depending on the brand.

How does Sugammadex work?

Sugammadex actions in the body deactivate rocuronium. It does this encapsulating the free molecule to form a stable complex. Sugammadex exerts its effect by forming very tight complexes at a 1:1 ratio with aminosteroid muscle relaxants creating intermolecular forces, thermodynamic bonds, and hydrophobic interactions. To make a tight sugammadex–rocuronium complex. This complex has a very high association rate and a very low dissociation rate. This results in a reduction in free rocuronium plasma concentration. So it creates a gradient between the tissue compartment and plasma so that the free rocuronium moves from tissue to plasma, with a reduction in nicotinic receptor occupancy at the Neuro-Muscular Junction.

Finding Sugammadex Manufacturers and Suppliers:

The process of finding trusted Sugammadex manufacturers and Sugammadex suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. It is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of Sugammadex. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier.